Young Gregory R, Smith Darren L, Embleton Nicholas D, Berrington Janet E, Schwalbe Edward C, Cummings Stephen P, van der Gast Christopher J, Lanyon Clare
Faculty of Health and Life Sciences, University of NorthumbriaNewcastle upon Tyne, United Kingdom.
Newcastle Neonatal Service, Newcastle upon Tyne Hospitals NHS Foundation TrustNewcastle upon Tyne, United Kingdom.
Front Cell Infect Microbiol. 2017 Jun 6;7:237. doi: 10.3389/fcimb.2017.00237. eCollection 2017.
Necrotising enterocolitis (NEC) and sepsis are serious diseases of preterm infants that can result in feeding intolerance, the need for bowel resection, impaired physiological and neurological development, and high mortality rates. Neonatal healthcare improvements have allowed greater survival rates in preterm infants leading to increased numbers at risk of developing NEC and sepsis. Gut bacteria play a role in protection from or propensity to these conditions and have therefore, been studied extensively using targeted 16S rRNA gene sequencing methods. However, exact epidemiology of these conditions remain unknown and the role of the gut microbiota in NEC remains enigmatic. Many studies have confounding variables such as differing clinical intervention strategies or major methodological issues such as the inability of 16S rRNA gene sequencing methods to determine viable from non-viable taxa. Identification of viable community members is important to identify links between the microbiota and disease in the highly unstable preterm infant gut. This is especially important as remnant DNA is robust and persists in the sampling environment following cell death. Chelation of such DNA prevents downstream amplification and inclusion in microbiota characterisation. This study validates use of propidium monoazide (PMA), a DNA chelating agent that is excluded by an undamaged bacterial membrane, to reduce bias associated with 16S rRNA gene analysis of clinical stool samples. We aim to improve identification of the viable microbiota in order to increase the accuracy of clinical inferences made regarding the impact of the preterm gut microbiota on health and disease. Gut microbiota analysis was completed on stools from matched twins ( = 16) that received probiotics. Samples were treated with PMA, prior to bacterial DNA extraction. Meta-analysis highlighted a significant reduction in bacterial diversity in 68.8% of PMA treated samples as well as significantly reduced overall rare taxa abundance. Importantly, overall abundances of genera associated with protection from and propensity to NEC and sepsis such as: , and sp. were significantly different following PMA-treatment. These results suggest non-viable cell exclusion by PMA-treatment reduces bias in gut microbiota analysis from which clinical inferences regarding patient susceptibility to NEC and sepsis are made.
坏死性小肠结肠炎(NEC)和败血症是早产儿的严重疾病,可导致喂养不耐受、需要进行肠切除、生理和神经发育受损以及高死亡率。新生儿医疗保健的改善使早产儿的存活率提高,导致患NEC和败血症风险增加的人数增多。肠道细菌在预防或引发这些疾病方面发挥作用,因此,已使用靶向16S rRNA基因测序方法对其进行了广泛研究。然而,这些疾病的确切流行病学情况仍然未知,肠道微生物群在NEC中的作用仍然难以捉摸。许多研究存在混杂变量,如不同的临床干预策略,或存在重大方法学问题,如16S rRNA基因测序方法无法区分活菌和死菌。识别活菌群落成员对于确定高度不稳定的早产儿肠道中微生物群与疾病之间的联系很重要。这一点尤为重要,因为残留DNA很稳定,在细胞死亡后仍会存在于采样环境中。螯合此类DNA可防止下游扩增并避免其纳入微生物群特征分析。本研究验证了单叠氮丙锭(PMA)的用途,PMA是一种DNA螯合剂,不会被未受损的细菌膜吸收,可减少与临床粪便样本16S rRNA基因分析相关的偏差。我们旨在改进对活菌微生物群的识别,以提高关于早产儿肠道微生物群对健康和疾病影响的临床推断的准确性。对接受益生菌治疗的同卵双胞胎(n = 16)的粪便进行了肠道微生物群分析。在提取细菌DNA之前,样本用PMA处理。荟萃分析突出显示,68.8%的经PMA处理的样本中细菌多样性显著降低,总体稀有分类群丰度也显著降低。重要的是,经PMA处理后,与预防和引发NEC及败血症相关的属的总体丰度,如:、和sp. 有显著差异。这些结果表明,通过PMA处理排除死细胞可减少肠道微生物群分析中的偏差,从而据此对患者患NEC和败血症的易感性进行临床推断。